395: Biotech investors' plea to Trump, and a busy M&A week
About this episode
The episode discusses the impact of FDA decisions on biotech investments and features a conversation with investor Rod Wong about regulatory flexibility.
How has the Food and Drug Administration's recent decisions on rare disease drugs affected investment trends? Why is Eli Lilly getting into sleep medicine? And where did Allison go on her vacation? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's weekly biotech podcast. Biotech investor Rod Wong joins us to talk about why an industry-patient coalition he's part of sent a letter to President Trump asking for more regulatory flexibility at the FDA. We also discuss the U.S. approval of Eli Lilly's obesity pill, recent deal-making by large pharma companies, a strange story about promotion of psychedelic drugs on YouTube, and more.
People in this episode
Guest: Rod Wong
Topics covered
- biotech investment
- FDA decisions
- rare disease drugs
- Eli Lilly
- M&A activity
- psychedelic drugs
Keywords
- biotech
- FDA
- investment trends
- Eli Lilly
- M&A
- rare diseases
- psychedelic drugs
Mentioned in this episode
Organizations: Food and Drug Administration, Eli Lilly, STAT
Products: obesity pill, sleep medicine
More episodes of The Readout Loud
- 398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts
- 397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment
- 396: A new trick for old science, and biotech VCs' scrambled playbook
- 394: Eli Lilly's deal man, Allogene's off-the-shelf CAR-T, and Merck's Terns buy
- 393: A conversation with the 'godfather' of biotech
- 392: Epstein's pal attempts a biotech comeback, and Prasad exits the FDA
Explore listener stats, chart rankings, contacts and more on the The Readout Loud podcast page.